Overview

Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL

Status:
Active, not recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

The investigators propose a treatment strategy where patients are treated with induction chemoimmunotherapy consisting of rituximab + bendamustine for 6 cycles, followed by initiation of maintenance rituximab and lenalidomide among patients achieving an objective response (i.e., at least stable disease with some tumor shrinkage) to induction therapy. The goal of maintenance therapy will be to capitalize on the cytoreduction following induction chemotherapy with a maintenance regimen that has also shown promising activity in CLL, in order to allow for improved PFS in this population.

Phase:

Phase 2

Details

Lead Sponsor:

University of Wisconsin, Madison

Collaborators:

Celgene Corporation
Genentech, Inc.

Treatments:

Bendamustine Hydrochloride
Lenalidomide
Rituximab
Thalidomide